NCT07091799Recruiting
Interest of Measuring P2X4 Receptors on Blood Monocytes as a Diagnostic Marker in Amyotrophic Lateral Sclerosis: P2X4 as a Diagnostic Biomarker for ALS
Source: ClinicalTrials.gov · Last updated 21 Jan 2026
Brief summary (registry, in English)
Amyotrophic lateral sclerosis (ALS) is the most common form of motor neuron disease and is characterized by the degeneration of motor neurons leading to progressive paralysis and death within 3 to 5 years after diagnosis. To date, no key mechanism had been identified. Our associated laboratory has identified the P2X4 purinergic pathway that appears to be involved in the pathogenesis of ALS. Our goal is to verify these results at the human level in order to have a proof of concept of P2X4's role as a biomarker of the disease.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 25 Jun 2025
- Start date
- 15 Jan 2026
- Primary completion date
- Jan 2027
- Lead sponsor
- University Hospital, Bordeaux
- Diseases
- ALS (motor neurone disease)
- NCT number
- NCT07091799
What you commit to
- Study type: Interventional
- Planned participants: 50
- From 15 Jan 2026 to the primary completion date, Jan 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- People undergoing immunosuppressive or corticosteroid treatments.
Other
- Participation in a research protocol with an experimental treatment.
- People placed under guardianship, curatorship or legal protection.
- For healthy volunteer, people directly related to the patient (siblings, descendants and ancestry).
Who the study is looking for
- For ALS group: Person presenting a probable or confirmed diagnosis of ALS according to the criteria of EI Escorial.
- Adult.
- Person affiliated or beneficiary of a social security scheme.
- Free, informed and written consent signed by the participant or by a third person (in case of physical incapacity of the participant), after information on the study.
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hopital Pellegrin Coordinator of this site? Confirm its status | Bordeaux | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.